• The Company
    • Who we are
    • Partner Portal
  • Meet the Partners
  • Our Approach
  • Portfolio
    • Current Portfolio
    • Historic Portfolio
  • News
  • Contact Us
The Vertical Group
Investing for Innovation

Omada Health Expects to Tip the Scale at "Hundreds of Thousands" of Individual Users by 2016

9/25/2015

 
Via: The Business Journals 
Omada Health, which just nabbed $48 million in new funding, expects to have "hundreds of thousands" of health plan enrollees using its digital health services by next year, CEO Sean Duffy says.

The San Francisco-based startup helps people with obesity-related chronic diseases get healthier. But it sells its services to health insurers and big employers, who benefit when their enrollees or employees make healthier choices.

About 20,000 patients use its platform currently, a number that's expected to jump by an additional 10,000 by year-end, Duffy told me this week. But by next year, he projects that "hundreds of thousands" of individuals will be using Omada Health to deal with chronic conditions like obesity and diabetes, in many cases before they reach the "tipping point" where they topple into experiencing the full-fledged medical condition.

Read More: 
http://www.bizjournals.com/sanjose/blog/techflash/2015/09/omada-sean-duffy-digital-health.html?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+bizj_sanjose+%28Silicon+Valley+%2F+San+Jose+Business+Journal%29

OncoMed Presents Immuno-Oncology Data for GITRL-Fc Candidate at the Inaugural International Cancer Immunotherapy Conference

9/16/2015

 
Via: OncoMed
NEW YORK and REDWOOD CITY, Calif., Sept. 16, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, today presented preclinical data for the company's proprietary, wholly owned GITRL-Fc agent during the afternoon poster session of the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference.

GITRL is a member of the tumor necrosis factor (TNF) family of ligands and functions to activate the co-stimulatory receptor GITR (glucocorticoid-induced tumor necrosis factor receptors) to enhance T-cell modulated immune responses. OncoMed's GITRL-Fc agent is engineered using a novel single-gene linkerless GITRL trimer which enables effective GITR activation and robust anti-tumor immune response.
​
"The single-gene linkerless trimer technology we have created provides a flexible platform for the design of additional immuno-oncology agents, including bispecific agents," said Austin Gurney, PhD, Senior Vice President of Molecular and Cellular Biology. "We observed improved activation of GITR and highly potent single-agent activity using our GITRL fusion protein, and also noted that GITRL-Fc shows strong additivity with other immune checkpoint blockers. These data demonstrate a powerful new class of immunotherapeutic agent."

Read More: http://investor.shareholder.com/oncomed/releasedetail.cfm?ReleaseID=931976

Omada Health, Which Pioneered Digital Therapeutics, Raises $48 Million In Series C Round

9/16/2015

 
Via: Forbes
Omada Health, which provides a digital program based on the landmark NIH diabetes prevention study, raised $48 million, bringing total funding to $77.5 million. The series C round was led by Norwest Venture Partners, and includes returning investors Andreessen Horowitz and US Venture Partners, among others. Accelerator-turned venture fund Rock Health which nurtured Omada in its first class of digital health startups, also reinvested.

In a significant vote of confidence, two of Omada’s customers, Humana HUM -2.29% and Providence Health & Services also joined the round. The two health plans started offering Omada’s Prevent program less than a year ago to their employees and members. Those who enrolled registered a weight loss of 4% to 6%. “It’s one if the key reasons that sparked their interest; they were thrilled with the results,” says Omada’s co-founder and CEO Sean Duffy. (Kaiser Permanente is another customer/investor.) 

Participants who are at risk of developing diabetes enroll in a 16-week program that focuses on healthy eating and exercise. They are placed in groups of 10 to 12, based on age, body mass index (BMI) and residence, and work with a “health coach” who tracks their progress and lends extra support. After completing Prevent, participants can continue to receive support.

Read More: ​http://www.forbes.com/sites/zinamoukheiber/2015/09/16/omada-health-which-pioneered-digital-therapeutics-raises-48-million-in-series-c-round/#264f592f59a7

    Archives

    December 2020
    December 2019
    November 2019
    October 2019
    August 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    April 2015
    March 2015
    February 2015
    January 2015
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    February 2014
    January 2014
    December 2013
    October 2013
    August 2013
    July 2013
    June 2013
    May 2013
    April 2013
    March 2013
    February 2013
    January 2013

    RSS Feed

© The Vertical Group - info@vertical-group.com
 PO 218, Berkeley Heights, NJ 07922 | (908) 277-3737
PO 5006, San Mateo, CA  94402 | (650) 566-9060
Picture
Website by Custom Dynamics